Optivar is an eye drop used for treating itchy eyes caused by allergies. It belongs to a class of medications called antihistamines and works by blocking a specific type of histamine receptor in the body. This prescription eye medication comes in the form of an eye drop and is typically used in each eye twice a day. Potential side effects include burning, headaches, and a bitter taste.
What Is Optivar?
Optivar® (azelastine ophthalmic solution) is a prescription eye drop used for the treatment of eye allergies. In particular, this medication is approved for treating itchy eyes caused by allergies (known medically as allergic conjunctivitis).
Optivar is manufactured by Patheon UK, Ltd. (6 mL size), or Catalent Pharma Solutions (0.2 mL size) and is marketed and distributed by Meda Pharmaceuticals, Inc.
How Does Optivar Work?
Optivar is part of a class of drugs called antihistamines. Specifically, it is an H1 receptor antagonist. This means that it blocks a specific type of histamine receptor in the body (known as H1 receptors). Because allergic reactions are partly caused by the release of histamine from certain cells in the body, Optivar can help relieve or prevent allergy symptoms.
In addition to blocking histamine receptors, Optivar also seems to decrease the release of histamine from the cells in the body and may also inhibit other substances (such as leukotrienes), which are produced by the body in response to an allergen.
In clinical studies, Optivar was shown to prevent and relieve itching of the eyes due to allergies. In these studies, a dose of this medication was shown to start working quickly (within three minutes) and last for about eight hours.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed July 14, 2010.
Meda Pharmaceuticals. Meda has settled the U.S. Astelin® patent litigation with Apotex (4/21/2008). Meda Web site. Available at: http://www.meda.se/english/news/year_2008/meda_has_settled_the_us_astelin_patent_litigation_with_apotex.pdf. Accessed August 7, 2009.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 8th ed. Philadelphia (PA): Lippincott Williams & Wilkins;2008.
National Library of Medicine (US). Drugs and Lactation Database (LactMED). NLM Web site. Available at: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT. Accessed January 26, 2009.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click